Norma Cavazos-Rocha

Norma Cavazos-Rocha

Auto-generated profile, based on publicly available information

Norma Cavazos-Rocha

Universidad Autonóma de Nuevo León

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
CMCarmen Molina-Torres
Carmen Molina-Torres
ABAlejandra Barba-Marines
Alejandra Barba-Marines
OVOrestes Valles-Guerra
Orestes Valles-Guerra
JOJorge Ocampo-Candiani
Jorge Ocampo-Candiani
NCNorma Cavazos-Rocha
Norma Cavazos-Rocha
LVLucio Vera-Cabrera
Lucio Vera-Cabrera
Due to the emergency of multidrug-resistant strains of Mycobacterium tuberculosis, is necessary the evaluation of new compounds.

16 March 2018 in Reviews in Analytical Chemistry
Verified
Journal Article
Open access
PDF file
OPOmar J. Portillo-Castillo
Omar J. Portillo-Castillo
RCRocío Castro-Ríos
Rocío Castro-Ríos
ACAbelardo Chávez-Montes
Abelardo Chávez-Montes
AGAzucena González-Horta
Azucena González-Horta
NCNorma Cavazos-Rocha
Norma Cavazos-Rocha
MTMarsela Garza Tapia
Marsela Garza Tapia
Solid-phase microextraction (SPME) is a sample preparation technique with many applications that is being continuously developed. In this technique, the type of fiber coating plays a crucial role for extraction efficiency. Currently available commercial coatings have certain drawbacks that have been overcome by the development of new coatings based on novel materials; these have improved the efficiency of extraction, selectivity and stability of commercial coatings. Pharmaceutical and personal care products (PPCPs) are one of the most important groups of emerging contaminants; however, some studies suggest that these compounds can cause adverse health effects. No official monitoring protocols for these compounds are currently available, so the establishment of analytical methods that allow their determination in environmental samples is required. The complexity of environmental samples together with the low concentration levels of these compounds makes necessary the use of sample preparation techniques capable of removing interferences, as well as preconcentrated analytes, and SPME is a very promising alternative to achieve this. This review describes the recent developments in SPME with classical and novel coatings and its applications for PPCP determination in environmental samples.

11 January 2008 in Molecules
Verified
Journal Article
Open access
PDF file
NENelly Alejandra Espinoza-González
Nelly Alejandra Espinoza-González
OWOliverio Welsh
Oliverio Welsh
NTNoemi Waksman De Torres
Noemi Waksman De Torres
NCNorma Cavazos-Rocha
Norma Cavazos-Rocha
JOJorge Ocampo-Candiani
Jorge Ocampo-Candiani
LVLucio Vera-Cabrera
Lucio Vera-Cabrera
Two recently synthesized oxazolidinones: (R)-3-(4-(2-(2-methyltetrazol-5-yl)-pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyloxazolidin-2-one (DA-7157) and itscorresponding pro-drug (R)-3-(4-(2-(2-methyltetrazol-5-yl)-pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl) methyl disodium phosphate (DA-7218), have shown very goodactivity against several Gram positive bacteria, including Nocardia and Mycobacterium. Inthe present work we evaluated the therapeutic in vivo effects of DA-7218 on Nocardiabrasiliensis. We first determined the plasma concentration of the prodrug in BALB/c miceusing several doses and then tested its activity in an in vivo experimental actinomycetomamurine model. At the end of treatment, there was a statistically significant differencebetween the three drug receiving groups (25, 12.5 and 5 mg/kg) and the control group(saline solution) (p=0.001), proving that DA-7218 is effective for the treatment of experimental murine actinomycetoma. This compound could be a potential option forpatients affected with mycetoma by Nocardia brasiliensis.

1 June 2019 in Journal of Food Composition and Analysis
Verified
Journal Article
Closed access
DPDavid Paniagua-Vega
David Paniagua-Vega
NCNorma Cavazos-Rocha
Norma Cavazos-Rocha
AHAriana A. Huerta-Heredia
Ariana A. Huerta-Heredia
APAída Parra-Naranjo
Aída Parra-Naranjo
VRVerónica M. Rivas-Galindo
Verónica M. Rivas-Galindo
ASAlma L. Saucedo
Alma L. Saucedo

3 March 2014 in Journal of Chromatographic Science
Verified
Journal Article
Open access
PDF file
NCNorma Cavazos-Rocha
Norma Cavazos-Rocha
ICIdalia Carmona-Alvarado
Idalia Carmona-Alvarado
LVLucio Vera-Cabrera
Lucio Vera-Cabrera
NWNoemí Waksman-De-Torres
Noemí Waksman-De-Torres
MSMaría de la Luz Salazar-Cavazos
María de la Luz Salazar-Cavazos
A chromatographic method was implemented and validated for the simultaneous determination of antimicrobials proposed for the treatment of mycetoma: three fluoroquinolones: ciprofloxacin, moxifloxacin and sparfloxacin; two oxazolidinones: DA-7157 (DA2; torezolid) and its prodrug DA-7218 (DA1). Separation of analytes was achieved on an Atlantis dC18 column (150 × 4.6 mm i.d., 5 µm particle size) with a mobile phase composed of acetonitrile and trifluoroacetic acid 0.1% (v/v) using a gradient program. Total running time was 30 min. Quantification of sparfloxacin was carried out using a DAD at 278 nm; the oxazolidinones DA1 and DA2 and the quinolones ciprofloxacin and moxifloxacin were analyzed by fluorescence with an excitation wavelength of 292 nm and an emission wavelength of 525 nm. Intraday precision was in the range of 3.2 and 14.1%. Linearity range was from 0.3 to 10 µg/mL for sparfloxacin using DAD detector, and from 0.2 to 10 µg/mL for ciprofloxacin, 0.3 to 10 µg/mL forDA2, 0.4 to 10 µg/mL for DA1 and 0.04 to 10 µg/mL for moxifloxacin with fluorescence detector. Acetonitrile was used to precipitate proteins from plasma. Recoveries at low, medium and high concentration were between 80 and 120%. Limits of quantification were between 0.04 and 0.4 µg/mL in plasma. The method can be applied for individual or simultaneous determination of the antimicrobials in plasma.

16 October 2015 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
NGNorma Alejandra González-Martínez
Norma Alejandra González-Martínez
HLHector Gerardo Lozano-Garza
Hector Gerardo Lozano-Garza
JGJorge Castro Garza
Jorge Castro Garza
AOAlexandra De Osio-Cortez
Alexandra De Osio-Cortez
JVJavier Vargas-Villarreal
Javier Vargas-Villarreal
LVLucio Vera-Cabrera
Lucio Vera-Cabrera
Mycetoma is a neglected, chronic, and deforming infectious disease caused by fungi and actinomycetes. In Mexico, N. brasiliensis is the predominant etiologic agent. Therapeutic alternatives are necessary because the current drug regimens have several disadvantages. Benzothiazinones (BTZ) are a new class of candidate drugs that inhibit decaprenyl-phosphoribose-epimerase (DprE1), an essential enzyme involved in the cell wall biosynthesis of Corynebacterineae. In this study, the in vitro activity of the next generation BTZ, PBTZ169, was tested against thirty Nocardia brasiliensis isolates. The MIC50 and MIC90 values for PBTZ169 were 0.0075 and 0.03 μg/mL, respectively. Because Nocardia is a potential intracellular bacterium, a THP-1 macrophage monolayer was infected with N. brasiliensis HUJEG-1 and then treated with PBTZ169, resulting in a decrease in the number of colony-forming units (CFUs) at a concentration of 0.25X the in vitro value. The in vivo activity was evaluated after infecting female BALB/c mice in the right hind food-pad. After 6 weeks, treatment was initiated with PBTZ169 and its activity was compared with the first generation compound, BTZ043. Both BTZ compounds were administered at 100 mg/kg twice daily by gavage, and sulfamethoxazole/trimethoprim (SXT), at 100 mg/kg sulfamethoxazole, was used as a positive control. After 22 weeks of therapy, only PBTZ169 and SXT displayed statistically significant activity. These results indicate that DprE1 inhibitors may be useful for treating infections of Nocardia and may therefore be active against other actinomycetoma agents. We must test combinations of these compounds with other antimicrobial agents, such as linezolid, tedizolid or SXT, that have good to excellent in vivo activity, as well as new DprE1 inhibitors that can achieve higher plasma levels. Mycetoma is a neglected tropical disease caused by many etiological agents, including actinobacteria and true fungi. In Mexico, Nocardia brasiliensis and Actinomadura madurae account for more than 90% of the total cases. This subcutaneous infectious disease can affect skin and subcutaneous tissue; actinomycetomas are particularly osteolytic. The presence of abundant scar tissue, pus, and the intracellular growth of Nocardia make treatment very difficult. Current N. brasiliensis actinomycetoma therapy includes the use of trimethoprim-sulamethozaxole, diamino-diphenyl-sulphone (DDS), amikacin, and amoxicillin-clavulanate. N. brasiliensis is resistant to many other antimicrobials due in part to its richness in copies of genes related to pharmacoresistance, for instance rpoB, gyrase, beta-lactams, P450 cytochromes, etc. DprE1 inhibitors are new types of compounds that target a completely different gene, dprE1, encoding the decaprenylphosphoryl-d-ribose oxidase. Assays evaluating these experimental or other new drugs are necessary to develop a better therapeutic scheme for actinomycetoma, with more potent, less toxic antimicrobials.